RxDoctor Payments Data

Greg Alaestante, DO

Family Medicine · Phoenix, AZNPI 1710247887

Payments from drug & device makers

$734in general payments, 2019–2025

Across 15 payments — averaging $48.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$179
  • Inari Medical, Inc.$144
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
  • Penumbra, Inc.$124
  • Lilly USA, LLC$51
  • Novartis$37
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$348,302
Medicare patients
343
Services billed
4,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$52,322
EntrestoSacubitril/Valsartan13$11,553
MounjaroTirzepatide11$10,384
JanuviaSitagliptin Phosphate13$9,283
Rosuvastatin Calcium192$3,146
Levothyroxine Sodium150$1,594
Atorvastatin Calcium179$1,570
Metoprolol Succinate68$1,279
Carbidopa-LevodopaCarbidopa/Levodopa13$1,247
Tamsulosin Hcl64$1,074
Losartan Potassium104$930
Ezetimibe38$910
Duloxetine Hcl30$878
Ibandronate Sodium29$845
Amlodipine Besylate84$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$37$11,55313 claims
Lilly USA, LLCMounjaro$51$10,38411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →